Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss.

Diamond P, Labrinidis A, Martin SK, Farrugia AN, Gronthos S, To LB, Fujii N, O'Loughlin PD, Evdokiou A, Zannettino AC.

J Bone Miner Res. 2009 Jul;24(7):1150-61. doi: 10.1359/jbmr.090210. Review.

2.

Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis.

Vandyke K, Dewar AL, Farrugia AN, Fitter S, Bik To L, Hughes TP, Zannettino AC.

Leukemia. 2009 May;23(5):994-7. doi: 10.1038/leu.2008.356. Epub 2008 Dec 18. No abstract available.

PMID:
19092851
3.

Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1alpha in patients with multiple myeloma.

Martin SK, Dewar AL, Farrugia AN, Horvath N, Gronthos S, To LB, Zannettino AC.

Clin Cancer Res. 2006 Dec 1;12(23):6973-7.

4.

RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone.

Atkins GJ, Kostakis P, Vincent C, Farrugia AN, Houchins JP, Findlay DM, Evdokiou A, Zannettino AC.

J Bone Miner Res. 2006 Sep;21(9):1339-49.

5.

Imatinib as a potential antiresorptive therapy for bone disease.

Dewar AL, Farrugia AN, Condina MR, Bik To L, Hughes TP, Vernon-Roberts B, Zannettino AC.

Blood. 2006 Jun 1;107(11):4334-7. Epub 2006 Jan 31.

PMID:
16449525
6.

An in vitro osteoclast-forming assay to measure myeloma cell-derived osteoclast-activating factors.

Zannettino AC, Farrugia AN, To LB, Atkins GJ.

Methods Mol Med. 2005;113:245-56.

PMID:
15968108
7.

Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.

Zannettino AC, Farrugia AN, Kortesidis A, Manavis J, To LB, Martin SK, Diamond P, Tamamura H, Lapidot T, Fujii N, Gronthos S.

Cancer Res. 2005 Mar 1;65(5):1700-9.

8.
9.

The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro.

Pan B, To LB, Farrugia AN, Findlay DM, Green J, Gronthos S, Evdokiou A, Lynch K, Atkins GJ, Zannettino AC.

Bone. 2004 Jan;34(1):112-23.

PMID:
14751568
10.

Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo.

Farrugia AN, Atkins GJ, To LB, Pan B, Horvath N, Kostakis P, Findlay DM, Bardy P, Zannettino AC.

Cancer Res. 2003 Sep 1;63(17):5438-45.

Supplemental Content

Loading ...
Support Center